Grifols (NASDAQ:GRFS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Grifols (NASDAQ:GRFS - Free Report) from a buy rating to a strong-buy rating in a report issued on Saturday.

Separately, JPMorgan Chase & Co. lifted their target price on shares of Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th.

Grifols Stock Up 2.0%

GRFS traded up $0.17 during trading on Friday, reaching $8.54. 935,804 shares of the stock traded hands, compared to its average volume of 1,155,233. The stock's 50-day simple moving average is $7.92 and its two-hundred day simple moving average is $7.62. The company has a debt-to-equity ratio of 1.13, a current ratio of 2.60 and a quick ratio of 0.97. Grifols has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The stock has a market cap of $5.87 billion, a price-to-earnings ratio of 7.30, a price-to-earnings-growth ratio of 0.32 and a beta of 0.53.

Institutional Investors Weigh In On Grifols

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Capital World Investors boosted its position in shares of Grifols by 0.7% in the fourth quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company's stock valued at $157,239,000 after acquiring an additional 154,358 shares during the period. Brandes Investment Partners LP boosted its holdings in Grifols by 3.0% in the 4th quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company's stock valued at $152,491,000 after purchasing an additional 592,096 shares during the period. Black Creek Investment Management Inc. boosted its holdings in Grifols by 1.3% in the 4th quarter. Black Creek Investment Management Inc. now owns 11,251,960 shares of the biotechnology company's stock valued at $83,715,000 after purchasing an additional 141,615 shares during the period. Soleus Capital Management L.P. grew its position in Grifols by 46.1% in the 4th quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company's stock worth $49,144,000 after purchasing an additional 2,083,722 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Grifols by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company's stock worth $29,948,000 after purchasing an additional 80,507 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.